Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (950)	2/8/2002 5:28:00 PM
From: keokalani'nui	Read Replies (3) \| Respond to of 2243

I was thinking biofreaks might collaborate to identify BTs that will present human results at ’02 ASCO that will support or erode investment value. From a search of SI and to some degree Y!, here is a short, preliminary list. Please contribute what you know, suspect or hope whether it be enlargement or refinement. I will try to reorganize and expand as (if) the base builds. Rick may kick me (us) off here any time, hopefully due the idea’s success, and we will then find our own home. Personal comments are very welcome, especially as they relate to the likelihood of success and its interplay with embedded scientific and investment expectations. In fact all comments are welcome, especially animated, critical comments accompanied by explanation or good humor. At a minimum, the eventual list could be used to quickly search the on-line abstracts by sponsor. ASCO starts May 18th, and so I figure anything worth knowing needs to be shared by the end of March. MLNM x341 (mm and solid tumors, P2?). No other drug is as important to such a highly valued BT than x341. An interesting question is how much more data will be disclosed than is already known. I would rate scientific and investments expectations as very high, the highest. TELK x286. P1 in multiple cancers. A very big deal to this company. Not sure what novel data might be disclosed. TLRK x67 (P2 BrCa, nslc, cc and glioma) ONXX 43-9006 IMCL H&N C225 refractory and first line. Trial designs will be under intense scrutiny. Mogan x98 P2 H&N IMGN Interim HuC242-DM1 P1/2 refr NSCL, pancreatic and colorectal. IMGN P1/2 HuN901-DM1 refractory sclc It would also be valuable to identify drug types, targets or MOA for which you think there will be significant data this year. This might draw into the discussion programs pursued by pharma.

To: scaram(o)uche who wrote (950)	2/8/2002 6:31:57 PM
From: Jim H	Read Replies (1) \| Respond to of 2243

Rick: I don't post often due to my extreme ignorance. However, I came across one that seems to fit the mold around here. The stock is BioReliance (BREL). They have labs around the world where they do contract research and manufacturing. Established company. Profitable. Ascending top line. Reasonable PE. Also a bio terrorism play. I believe that BREL will stand to benefit from increased activity in the biotech sector. Trickle stock. Good presentation at JPM H&Q available on web. Jim H